ESMO
Interviews and expert commentary tagged “ESMO” — the latest oncology research and clinical practice from the Audio Journal of Oncology.
Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy
Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy
Martin Wermke MD; ESMO 2025: Initial Therapy with Bi-Specific T-cell Engager Tarlatamab Promises Better Outcomes in Patients with Small Cell Lung Cancer
Tarlatamab, a bi-specific T-cell engager drug added to innitial immunochemotherapy brought encouraging initial survival outcomes in the DeLLphi-303 reported at the European Society for Medical Oncolog
Javier C Cortés MD PhD: ESMO 2025, Berlin: Initial Therapy with Sacituzumab Govitecan Improves Progression-Free Survival in Patients with Newly-Diagnosed Metastatic Triple Negative Breast Cancer—ASCENT-03 study
Javier Cortés tells his findings from ASCENT-03 as reported to ESMO 2025 in Berlin with antibody drug conjugate as initial therapy for TNBC in patients testing negative for PD-1/PD-L1
James Larkin FRCP, PhD: CheckMate 067 Study 10-Year Data Show Advanced Melanoma Landscape Transformed by Combo Checkpoint Inhibitor Therapy
James Larkin FRCP, PhD talks about the big changes in survival prospects for patients with advanced and metastatic melanoma that have take place over the last 10 years thanks to combination checkpoint
Rebecca Dent MD: ESMO Previous Highlights: Neo-Adjuvant Therapy for Triple Negative Breast Cancer, Checkpoint Inhibition, AI, Cancer Vaccines, and More ……
Rebecca Dent surveys the most recent ESMO Annual Meeting to prepare our thoughts for the ESMO 2025 meeting